C-RAD AB Secures $10 Million Order from U.S. Cancer Center

Stockholm, June 27, 2025 — C-RAD AB, a prominent healthcare equipment and supplies company specializing in radiation therapy solutions, has announced a significant order from a leading American cancer center. The order, valued at 10 million Swedish kronor (approximately $1 million USD), is set to equip a newly established satellite facility in Texas with advanced radiation therapy systems.

The contract includes the delivery of C-RAD’s Catalyst+ HD and Sentinel 4DCT systems. These systems are designed to enhance patient positioning and resource management, aligning with the clinic’s goal to commence patient treatments by 2027. The Catalyst+ HD is known for its high-definition optical surface scanning capabilities, while the Sentinel 4DCT provides advanced surface image-guided radiation therapy solutions.

C-RAD AB, headquartered in Uppsala, Sweden, operates through two main segments: Positioning and Imaging. The company is renowned for its innovative solutions in radiation therapy, including 4D SIGRT solutions, advanced particle therapy solutions, and enhanced positioning solutions for tomotherapy. C-RAD also offers a range of laser positioning products and an X-ray detector optimized for electronic portal imaging devices.

This new order underscores C-RAD’s expanding footprint in the United States and its commitment to advancing patient care through cutting-edge technology. The company, listed on the Swedish Stock Exchange, has a market capitalization of 1.15 billion SEK. As of May 29, 2025, C-RAD’s close price was 33.5 SEK, with a 52-week high of 49.5 SEK and a low of 26.05 SEK.

C-RAD’s partnership with XECAN aims to further develop products that enhance patient positioning and resource management within radiation therapy. The company continues to offer comprehensive services, including installation, application training, and aftersales support, ensuring seamless integration and operation of its systems.

This development is expected to positively impact C-RAD’s financial outlook, as the company continues to strengthen its presence in the global healthcare market. The order is a testament to C-RAD’s reputation for delivering high-quality, innovative solutions that meet the evolving needs of healthcare providers worldwide.